Similarly, Craddock et al. demonstrated that CCR2b-modified GD2-CAR enhanced tumor trafficking in a neuroblastoma model (39), and Moon et al. revealed that CCR2-modified Msln-CAR T cells enhanced tumor eradication in a pleural mesotheliomas model (40). This evidence concerns the gene MSLN and neoplasm.